论文部分内容阅读
目的通过水溶性化学小分子蛋白磷酸酶2A抑制剂LB1与阿霉素(doxorubicin,DOX)联合应用,研究其在肝癌化疗过程中的协同作用。方法体外细胞活性分析检测不同剂量LB1对HepG2细胞活性影响及其与阿霉素(DOX)的协同杀伤效应;通过裸鼠体内荷瘤模型以及组织化学分析,进一步观察LB1对肿瘤生长影响以及在体与阿霉素的协同化疗作用。结果 LB1对HepG2细胞生长与作用剂量相关,低剂量时可促进其生长,高剂量时则促进其凋亡,而且在联合阿霉素后,可显著提高对HepG2肿瘤细胞的杀伤作用;体内实验也发现,单纯给予阿霉素抑瘤率为57%,而LB1联合应用后,抑瘤率可达77%,显著提高了阿霉素对肿瘤的杀伤作用(P<0.05),且无明显毒副作用。结论 LB1联合应用可显著提高阿霉素(DOX)对肝癌细胞的化学杀伤作用。
Objective To investigate the synergistic effect of LB1, a water-soluble chemical small molecule protein phosphatase 2A inhibitor, and doxorubicin (DOX) in the chemotherapy of hepatocellular carcinoma (HCC). Methods The in vitro cell viability assay was used to detect the effect of different doses of LB1 on HepG2 cell activity and its synergistic killing effect with doxorubicin (DOX). The effects of LB1 on tumor growth were observed by in vivo tumor model and histochemical analysis in nude mice, Cooperative chemotherapy with doxorubicin. Results The growth of HepG2 cells was related to the dose of HepG2 cells. Low dose of LB1 promoted the growth of HepG2 cells, and promoted the apoptosis of HepG2 cells when treated with high dose of Adiponectin. The combination of doxorubicin and LB1 significantly enhanced the killing effect on HepG2 tumor cells. The results showed that the inhibition rate of doxorubicin alone was 57%, while the combined inhibition of LB1 was 77%, which markedly enhanced the killing effect of doxorubicin on tumor (P <0.05), and had no obvious side effects . Conclusion The combination of LB1 can significantly enhance the doxorubicin (DOX) on the chemical killing of liver cancer cells.